Clinical Research Sites: Navigating Growth, Investment and Partnership Opportunities – 2027 Outlook
Is Now the Right Time to Explore a Sale of Your Clinical Research Site?
Clinical research sites serve a critical function in bringing new therapies to market, connecting pharmaceutical sponsors with the patients and clinical data needed to evaluate safety and efficacy for novel therapies. These businesses operate through several models, including freestanding sites, embedded programs within physician practices and health systems, and integrated networks supported by site management organizations (SMOs). Some conduct studies across a broad range of therapeutic areas, while others specialize in therapeutic categories such as central nervous system (CNS) disorders, oncology, metabolic disease or immunology. Across these models, the ability to identify and enroll eligible patients, execute on complex protocols and produce reliable clinical data makes research sites essential partners to sponsors and contract research organizations (CROs).
The sector has attracted significant attention from private equity investors and strategic buyers seeking exposure to the pharmaceutical space through the businesses that support clinical development. An extensive drug development pipeline, increasingly specialized therapies and demanding trial requirements support the need for capable research site partners. Investors also see opportunities to build scale in a fragmented market through acquisitions, new site openings and therapeutic expansion. Centralized recruitment, contracting, technology and administrative functions can provide individual sites with resources to improve performance while allowing investigators and clinical teams to focus on study execution.
For owners of site businesses, investor and strategic buyer interest creates an opportunity to evaluate how a partnership could support their organization’s next phase of growth. Based on PGP’s experience, the right partner may provide capital for expansion, access to additional sponsor relationships, stronger recruitment capabilities and the infrastructure needed to manage a larger portfolio of studies. Transaction readiness, however, depends on more than just favorable sector dynamics. PGP has identified principal investigator continuity and reputation, enrollment performance, backlog, and compliance history as characteristics that influence how buyers assess a business. PGP approaches these factors by evaluating the organization’s competitive position, the sustainability of its earnings profile and its owners’ objectives, helping determine whether to pursue a partnership today or strengthen specific areas of the business before approaching the market.
What Is Driving Private Equity and Strategic Buyer Interest in Site Management Organizations?
The investment thesis for clinical research sites centers on growing demand for outsourced trial execution and the opportunity to build scale in a fragmented market. Advances in drug development, biologics and other novel therapies are creating development opportunities that require specialized investigators, niche patient populations and sophisticated clinical infrastructure. Emerging applications of artificial intelligence in discovery and development will further expand the pool of potential therapies over time.
It’s estimated that approximately half of global clinical development spending was outsourced to CROs in 2025, representing a roughly $60 billion market, with projections that estimate that outsourced spending could approach $100 billion by 2035 .1 While these estimates cover the broader clinical-stage CRO market rather than site management specifically, they illustrate the financial commitment to external development partners.
A major reason that sponsors outsource clinical research site services is that clinical trials have become more difficult to execute, with IQVIA reporting that the average number of endpoints per trial increased from 7.7 in 2016 to 8.5 in 2025. 2 More selective eligibility criteria, complex treatment protocols and extensive data collection requirements increase the burden on investigators and research staff. Studies targeting rare diseases or narrowly defined patient subgroups can make recruitment particularly challenging, while demanding visit schedules may complicate retention. These pressures strengthen the value of sites with established patient relationships, experienced coordinators and reliable processes for screening, enrollment and follow-up. For site organizations, these pressures create an opportunity to secure a greater share of study activity by demonstrating reliable enrollment and consistent delivery. Sponsors and CROs need partners that can deliver against study expectations while maintaining patient safety, protocol adherence and data integrity.
The market’s fragmented landscape provides additional rationale for investment with fewer than 10% of the estimated 25,000 sites belonging to broader networks. The site counts indicate a large independent site base which is especially conducive to the private equity model. Bringing sites together can allow a platform to coordinate study opportunities, standardize administrative functions and extend recruitment across multiple regions and geographies. Freestanding site models offer infrastructure built specifically for research, while embedded models can draw on existing physician relationships and clinical patient populations. Networks may combine these approaches, with differing levels of operational integration and centralized support. The investment opportunity therefore extends beyond increasing site count as buyers must demonstrate that a larger organization can deliver better execution, support productive investigators and maintain consistent quality across locations.
What Are the Different Research Site Operating Models and Paths to Scale?
Clinical research site networks can grow through freestanding research sites, embedded partnerships with existing physician practices, or a combination of both. Based on PGP’s experience working with different operating models, each approach creates a different balance of infrastructure investment, patient access, investigator engagement and operating control. For owners and investors, the key consideration is how effectively the model converts those resources into reliable enrollment, high-quality study execution and sustainable earnings.
Dedicated research sites operate from facilities designed primarily for clinical trials. These locations typically maintain their own research staff, equipment and investigator relationships, allowing management to exercise greater control over scheduling, training and study workflows. Concentrating activity in a dedicated facility can support efficient use of personnel and infrastructure, particularly as study volume increases. However, profitability depends on maintaining sufficient enrollment and study activity to absorb the fixed cost base. New locations may require meaningful investment before reaching an efficient operating scale.
Practice-embedded sites bring research capabilities into established clinical practices. The research organization may provide coordinators, contracting, regulatory support, recruitment resources and other administrative functions, while participating physicians serve as investigators. This structure can provide access to patients already receiving care for relevant conditions and reduce the need to build a separate clinical footprint. Its effectiveness depends on physician engagement, appropriate access to patient information and the ability to accommodate research alongside routine care.
Hybrid networks combine dedicated sites with embedded relationships, giving the organization flexibility to match its footprint to local patient populations and study requirements. A dedicated location may support more resource-intensive protocols, while practice partnerships can extend geographic reach or add therapeutic expertise.
| Dimension | Freestanding research sites | Practice-embedded sites | Hybrid Model |
|---|---|---|---|
| Practice access | Recruitment databases, referrals, community outreach and advertising | Existing practice populations, supplemented by outreach | Multiple recruitment channels across the network |
| Infrastructure | Greater responsibility for sites, equipment and staffing | Uses portions of an existing clinical footprint, with added research resources | Investment varies by location and protocol needs |
| Investigator relationships | Investigators may be employed or contracted | Investigators generally maintain clinical responsibilities within the practice | Mix of dedicated and practicing investigators |
| Operating control | More direct control over staffing and workflows | Requires coordination with practice leadership | Requires common standards across different site structures |
| Expansion approach | Open or acquire dedicated sites | Add physician partners and activate research capabilities | Select the structure best suited to each market |
| Principal execution risk | Underutilized capacity and fixed-cost absorption | Inconsistent physician participation or competing clinical priorities | Integration complexity and uneven site performance |
Based on PGP’s active mandates and proprietary conversations with buyers, the strongest operating model is one that the organization can replicate without compromising enrollment performance or clinical quality. Buyers will evaluate the economics of mature locations alongside the cost, timing and operational requirements of bringing new sites to scale.
How Should Clinical Research Sites Balance Specialization and Diversification?
Specialization can strengthen a network’s reputation and repeat study awards, particularly where investigators have demonstrated success with difficult protocols or narrowly defined patient populations. Diversification can reduce dependence on a single indication or funding cycle, but expansion into additional therapeutic areas introduces new training, equipment and recruitment requirements. For owners considering a transaction, therapeutic positioning should therefore be supported by enrollment relative to commitments, retention, repeat sponsor awards and profitability by study type.
| Therapeutic area | Representative indications | Key considerations for research sites |
|---|---|---|
| CNS: neurology and psychiatry | Alzheimer’s disease, Parkinson’s disease, depression, schizophrenia | Reliable assessments, trained raters, participant retention and caregiver involvement where applicable |
| Oncology and hematology | Solid tumors and blood cancers | Disease-specific patient access, molecular eligibility, specialist oversight and treatment infrastructure |
| Metabolic and endocrinology | Obesity, diabetes and MASH | Access to eligible populations, management of comorbidities and adherence over extended follow-up |
| Cardiovascular and renal | Heart failure, cardiovascular disease and chronic kidney disease | Physician referral relationships, longitudinal follow-up and coordination across specialties |
| Immunology and inflammatory disease | Rheumatoid arthritis, inflammatory bowel disease and other immune-mediated conditions | Specialist access, treatment-history screening and management of background therapies |
| Dermatology | Psoriasis, atopic dermatitis and other skin conditions | Consistent disease scoring, efficient visits and access to patients meeting severity requirements |
| Respiratory | Asthma, COPD and other pulmonary conditions | Pulmonary testing capabilities, appropriate patient identification and management of seasonal variability |
| Ophthalmology | Retinal disease, glaucoma and other eye conditions | Specialized imaging, equipment and experienced investigators |
| Infectious disease and vaccines | Preventive vaccines and infectious disease treatments | Rapid recruitment, population access and the ability to adjust capacity as study demand changes |
Selected categories are illustrative and may overlap; they are not intended to constitute a mutually exclusive market segmentation.
Differences among therapeutic areas shape staffing, equipment, recruitment strategies and study economics. For investors, therapeutic diversification can broaden a platform’s addressable opportunity, while significant penetration in selected indications can establish a stronger competitive position with sponsors. Headlands Research’s focus on CNS, vaccines and metabolic disease, and K2’s expertise in areas including Alzheimer’s disease, psychiatry and liver disease, illustrate different approaches to building that position.
What Supports Buyer Confidence in a Premium Research Site Business?
A research site network’s value depends on more than its number of sites, investigators or awarded studies. The central investment question that we’ve fielded in recent deals is whether the organization can consistently win studies, enroll appropriate patients and deliver reliable results. Scale and financial performance matter, but the quality of the underlying organization determines whether that performance can be sustained. Based on PGP’s conversations with buyers, experienced investigators, access to differentiated patient populations, strong sponsor relationships and clinical operations all contribute to a stronger investment proposition.
A central consideration is the business’s dependence on individual principal investigators (PIs). A respected PI can attract studies through therapeutic expertise, sponsor relationships and a strong execution record. However, a business whose revenue and relationships depend heavily on one investigator may face continuity and capacity questions. Buyers therefore evaluate both the reputation of the investigator team and the depth behind it, including succession planning, investigator retention and the ability to develop additional clinical leaders.
Diversification also shapes the assessment. Multiple locations can broaden patient access and provide additional capacity, particularly when they serve distinct referral networks and demographic groups. Coverage across therapeutic areas, sponsors, CROs and individual protocols can reduce exposure to changes in any single development program. Based on our experience, a network’s value depends on how effectively its locations operate together and whether quality remains consistent as the organization expands.
Additionally, commercial performance ultimately depends on two connected funnels – winning the study and enrolling the patient. The study funnel progresses from opportunity identification and feasibility assessment through site selection, award, contracting and activation. The patient funnel moves from lead generation and initial engagement through prescreening, informed consent, screening and enrollment or randomization, followed by retention through required visits. Buyers have voiced to PGP that they want visibility into conversion, timing and cost at each stage. Strong study awards have limited value without the ability to enroll, while recruitment capabilities generate revenue only when the site has appropriate studies available.
Lastly, quality and compliance underpin all of these factors as buyers have assessed inspection history, monitoring findings, protocol deviations, consent practices and the completeness of study records, alongside management’s response to identified issues in our recent processes. A strong organization can demonstrate that oversight is embedded in everyday operations and applied consistently across investigators and locations. Together, these capabilities help establish whether the business offers a repeatable platform for growth or remains dependent on a small number of people, relationships or studies.
| Buyer priority | What buyers evaluate |
|---|---|
| PI reputation and concentration | Investigator credentials, therapeutic expertise, sponsor feedback and performance history; revenue and study awards attributable to individual PIs; retention and succession plans. |
| Geographic reach and patient access | Distinct catchment areas, referral relationships and access to relevant demographic and disease populations; whether locations broaden recruitment rather than duplicate it. |
| Therapeutic area coverage | Demonstrated expertise and enrollment performance by therapeutic area; diversification supported by appropriate investigators, equipment and staff. |
| Sponsor, CRO and study concentration | Revenue, backlog and pipeline exposure to individual customers and protocols, including multiple studies dependent on the same sponsor or development program. |
| Study-winning capabilities | Feasibility response quality, site selection rates, repeat awards, contracting timelines and activation speed. |
| Patient recruitment and engagement | Recruitment sources, qualified patient access, conversion by stage, cost per enrolled patient, retention and visit completion. |
| Multisite execution | Performance by location, centralized support, consistent procedures, investigator oversight and evidence that new sites can become productive. |
| Quality and inspection history | FDA inspection outcomes where applicable, sponsor audit and monitoring findings, corrective actions and evidence that recurring issues have been resolved. |
For owners preparing for a transaction, the strongest positioning in PGP’s opinion connects historical results with a supportable growth plan. Demonstrating how existing capacity can support additional studies, how new investigators become productive and how expansion translates into earnings can make the investment case more credible. The objective is to show that future growth follows from capabilities that the organization has already established.
How Are Clinical Research Site Businesses Valued?
Valuing a clinical research site business requires both an assessment of historical earnings and a detailed understanding of how future studies will translate into revenue and profitability. Current performance provides a starting point, but buyers also evaluate the durability of those earnings as existing studies wind down and new protocols begin. A substantial backlog and active business development pipeline can support an attractive valuation when management can demonstrate how reliably those opportunities convert into revenue, over what timeframe and at what margin. Based on PGP’s recent transactions, backlog should therefore be viewed as an indicator of potential value rather than guaranteed revenue, as study delays, cancellations and changes in enrollment can affect its realization.
A credible forecast begins with clear definitions and study-level detail. Management should distinguish active studies, awarded studies awaiting startup, and opportunities that remain in the commercial pipeline, separating executed contracts from awards that are still subject to contingencies. For each study, projected revenue should reflect the site’s expected enrollment, contracted reimbursement, visit schedule and remaining study duration. Based on our experience, the overall size of a protocol is less informative than the revenue the individual site can reasonably earn within the forecast period. Buyers will also assess whether staffing, investigator availability and recruitment capacity can support the projected activity.
PGP uses historical conversion to provide the evidence needed to substantiate forecast assumptions. Sophisticated underwriting follows opportunities from initial feasibility and site selection through award, contracting, activation, first patient enrollment and revenue generation. Management should demonstrate both the percentage of opportunities that advance through each stage and the time required to do so. These patterns may differ by sponsor, CRO, therapeutic area and study type, making a single conversion assumption across the entire pipeline less impactful.
In PGP’s view, buyers will then evaluate how much of the annual budget is supported by revenue already earned and the expected in-year contribution from awarded studies, compared to how much remains dependent on winning additional work. This remaining “go-get” requirement is particularly important as the year progresses. A forecast that relies on new awards must allow sufficient time for contracting, startup, recruitment and patient visits before year-end.
Ultimately, valuation depends on the confidence buyers place in the earnings being underwritten. Consistent performance against budget, supported by transparent explanations of variances, can strengthen confidence in management’s projections. Conversely, repeated startup delays, optimistic enrollment assumptions or a large dependence on unawarded studies may lead buyers to reduce forecasted earnings or seek transaction terms that share the risk of future performance. In PGP’s view, owners can strengthen their positioning by presenting a clear bridge from historical results to projected revenue and EBITDA, supported by study-level operating data and demonstrated conversion performance.
Revenue visibility begins with a credible backlog. Awarded studies can support future growth, but their economic contribution depends on activation timing, enrollment, protocol changes and sponsor decisions. Strong reporting distinguishes potential study opportunities from awarded, activated and enrolling trials. It also translates those stages into realistic revenue expectations using historical performance rather than assuming that every award reaches its full contractual potential.
Enrollment performance connects clinical capabilities with financial results. Buyers should understand how quickly sites activate, whether enrollment commitments are achievable and how effectively participants remain engaged through required visits. A large patient database has limited value without evidence that the organization can identify eligible patients, secure appropriate participation and retain them throughout the protocol.
The two funnels should be tracked separately:
| Funnel | Stages to Track | Useful Measures |
|---|---|---|
| Win the Study | Opportunity → Feasibility → Site Selection/Award → Contracting → Activation | Feasibility-to-award conversion, award-to-activation conversion, repeat award rate and days between stages. |
| Enroll and Retain the Patient | Lead → Contacted/Interested → Prescreen → Consent/Screening → Enrolled/Randomized → Study Completion | Conversion and time between stages, screen failure rate, cost per randomized patient, retention and completed visits. |
Who Are the Most Active Buyers for Clinical Research Site Networks?
The buyer universe for site management organizations (SMOs) spans three principal groups, each with distinct investment rationale. Understanding these differences helps owners identify partners whose strategic objectives align with their clinical operations, research capabilities and growth priorities.
- Private Equity Firms and Family Offices: Investors seeking an initial platform investment from which to build a scaled clinical research organization through acquisitions, additional site locations and therapeutic area expansion. These buyers typically prioritize established investigator relationships, diversified sponsor relationships, experienced operational leadership and a scalable infrastructure capable of supporting continued growth.
- PE-Backed Site Management Organizations (SMO): Established site platforms seeking to expand their geographic reach, therapeutic expertise and depth of investigator relationships through strategic acquisitions. These organizations are often focused on adding high-performing research sites, accessing new sponsor relationships and strengthening their ability to execute clinical trials across a broader range of therapeutic indications.
- Global Clinical Research Organizations (CRO): Established CROs seeking to gain more direct access to investigators and patients, which helps win more studies and enroll patients faster. Owning that capability gives CROs more influence over a part of the trial that can determine whether it stays on schedule.
The table below highlights select private equity backed SMO platforms:
| Platform Name | Sponsor | Description |
|---|---|---|
| ACRS | Latticework Capital | Clinical research site network providing multi-therapeutic clinical trial management, patient recruitment and study execution services. |
| Adams Clinical | InTandem Capital | Multi-site clinical research organization specializing in CNS, psychiatry and neurological clinical trials. |
| Alcanza Clinical Research | Martis Capital | Multi-site clinical research platform conducting Phase I–IV trials across a broad range of therapeutic areas. |
| CenExel | BayPine | National research site network specializing in CNS, psychiatry, neurology and other complex therapeutic areas. |
| Clinical Research of West Florida | Fengate | Regional clinical research platform with Phase I–IV capabilities and expertise in autoimmune and rheumatology indications. |
| Eximia Clinical Research | VSS | Multi-site clinical research platform providing site management and trial execution services across multiple therapeutic areas. |
| Flourish Research | Genstar Capital | Multi-site research organization with expertise in cardiovascular, metabolic, neuroscience and infectious disease trials. |
| Headlands Research | THL Partners | Multinational clinical research site network partnering with pharmaceutical and biotechnology companies across diverse therapeutic areas. |
| Rovia | Gauge Capital | Multi-specialty clinical research site network focused on expanding patient access and clinical trial capabilities. |
| Velocity Clinical Research | GHO Capital | Scaled clinical research organization operating an integrated network of research centers across North America and Europe. |
| Pinnacle Clinical Research | LongueVue Capital | Specialized clinical research organization focused on hepatology, liver disease and metabolic disorders. |
Selecting the right partner requires evaluating more than headline valuation, with careful consideration on how a buyer will support the organization’s long-term growth and research capabilities. Key considerations that PGP helps to evaluate include the partner’s approach to investigator relationships, site-level operations, sponsor partnerships, investment in infrastructure and expectations for future expansion. The right partnership should provide capital, resources and operational support to scale the business while maintaining research quality, investigator engagement and continuity across existing sites.
Select Clinical Research Transactions and Platform Activity
The table below highlights select M&A transactions across the clinical research and site management organization (SMO) landscape, including platform investments and add-on acquisitions. PGP diligently tracks transaction activity which has served to illustrate the continued consolidation of the sector and provide insight into the strategic considerations that shape partnerships between research organizations and investors.
| Date | Buyer | Target | Description |
|---|---|---|---|
| February 2024 | PCM Trials | EmVenio Research | Decentralized clinical research organization providing mobile research services and access to diverse patient populations. |
| February 2024 | Headlands Research | Pharmasite Research | Multi-site clinical research organization conducting trials across a range of therapeutic areas. |
| March 2024 | Assured Healthcare Partners | Prolerity Clinical Research | Multi-site clinical research network focused on CNS, GI, cardiovascular and metabolic indications. |
| April 2024 | Alcanza Clinical Research | Innovation Medical Research Center | Clinical research site conducting trials across multiple therapeutic specialties. |
| May 2024 | InTandem Capital Partners | Adams Clinical | Multi-site clinical research organization specializing in CNS and psychiatric indications. |
| May 2024 | ACRS | Elixia | Clinical research organization with a 40-bed Phase I unit and expertise across multiple therapeutic areas. |
| June 2024 | Flourish Research | ENCORE Research Group | Multi-site clinical research organization conducting Phase I–IV trials across diverse therapeutic areas. |
| July 2024 | Eximia Research | Tidewater Clinical Research | Clinical research site conducting trials across multiple therapeutic indications. |
| Sep 2024 | Genstar Capital | Flourish Research | Multi-site clinical research platform with broad therapeutic expertise and an established investigator network. |
| Sep 2024 | Gauge Capital | Rovia Clinical Research | Multi-specialty clinical research site network conducting drug, device and diagnostic trials. |
| October 2024 | Eximia Research | Integrated Clinical Trial Services | Clinical research organization providing clinical trial management and site-based research services. |
| November 2024 | Headlands Research | Trial Management Associates | Clinical research organization providing site management and clinical trial execution services. |
| December 2024 | Adams Clinical | InSite Clinical Research | Clinical research site conducting trials across multiple therapeutic areas. |
| February 2025 | Flourish Research | Diablo Clinical Research | Clinical research organization conducting trials across a range of therapeutic indications. |
| April 2025 | BayPine | CenExel Clinical Research | National clinical research site network specializing in CNS, psychiatry and complex therapeutic areas. |
| May 2025 | Flourish Research | Center for Advanced Research & Education | Clinical research organization conducting trials across multiple therapeutic specialties. |
| July 2025 | Headlands Research | CMRCenter | Clinical research site conducting trials across multiple therapeutic areas. |
| August 2025 | THL Partners | Headlands Research | Multinational clinical research site network supporting pharmaceutical and biotechnology-sponsored trials. |
| August 2025 | Shore Capital | PhaseWell Research | Multi-site clinical research platform conducting Phase I–IV trials across multiple therapeutic areas. |
| Sep 2025 | QHP Capital | Vector Clinical Trials | Clinical research site platform focused on community-based trial execution and patient recruitment. |
| October 2025 | Flourish Research | Valkyrie Clinical Trials | Oncology-focused clinical research network conducting early- and late-phase cancer trials. |
| January 2026 | PhaseWell Research | Bio Behavioral Health | Clinical research site specializing in psychiatric and neurological indications. |
| March 2026 | PhaseWell Research | Chase Medical Research | Multi-site clinical research organization conducting pharmaceutical-sponsored clinical trials. |
| May 2026 | Thurston Group | Sensorium Clinical Research | Multi-site clinical research platform combining specialized research centers and laboratory capabilities. |
| May 2026 | Alliance Clinical Network | Atlas Clinical Research | Clinical research site network providing clinical trial services across multiple therapeutic areas. |
| June 2026 | Headlands Research | Clinical Trials Research (CTR) | Clinical research organization operating dedicated research sites and conducting sponsored clinical trials. |
| September 2026 | Summit Clinical Research Solutions / Pinnacle Clinical Research | Dallas Research Institute (DRI) | Clinical research site conducting trials across multiple therapeutic indications. |
| October 2026 | Fengate | Clinical Research of West Florida | Regional clinical research organization conducting Phase I–IV trials across diverse therapeutic areas. |
Through its broader focus on healthcare services, PGP maintains longstanding relationships with private equity firms, family offices and strategic acquirers active in the clinical research and site management landscape. These relationships provide research platform owners with access to a broad universe of financial and strategic buyers, including established SMOs and organizations seeking to expand their clinical trial capabilities, geographic reach and therapeutic expertise.
PGP Perspective
PGP believes clinical research site businesses are well positioned for continued investment as sponsors and CROs look for partners that can enroll eligible patients and execute increasingly complex trials. The opportunity is strongest for organizations that consistently win studies, meet enrollment commitments and maintain clinical quality as they expand. That can be true of a specialized site with deep investigator relationships and access to a hard-to-recruit patient population or a diversified network across multiple locations and therapeutic areas.
PGP helps clinical research site owners assess their readiness, identify partners that fit their objectives, and negotiate terms that support both the economics of the transaction and the long-term success of the research site. The right time to explore a transaction depends on what owners want to accomplish and how well the business can substantiate its growth plan. A financial sponsor may provide capital to build a broader platform while an established SMO may help extend geographic reach or add therapeutic capabilities and provide an opportunity to “roll equity”. Each brings different expectations for investigator autonomy, resources, and growth.
Interested in learning more about market insights, valuation trends, and strategic opportunities?
Speak to a Senior BankerSources & Citations
Physician Growth Partners · This content is provided for informational purposes only and does not constitute legal, financial, or investment advice. All transaction data sourced as cited. © 2026 Physician Growth Advisors, LLC. All rights reserved.
Latest Market Updates


Considering a healthcare transaction? Start with a confidential conversation.
"*" indicates required fields



